Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis

Leuk Res. 2008 Oct;32(10):1628-32. doi: 10.1016/j.leukres.2008.02.002. Epub 2008 Mar 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / immunology
  • Cyclin D
  • Cyclins / analysis*
  • Cyclins / genetics
  • Cyclins / immunology
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / mortality
  • Prognosis
  • Survival Analysis
  • Translocation, Genetic*

Substances

  • Biomarkers, Tumor
  • Cyclin D
  • Cyclins